A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of XZP-3621 versus crizotinib and to evaluate the pharmacokinetics of XZP-3621 in Chinese participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 1:1 into one of the two treatment groups to receive either XZP-3621 (500 milligrams \[mg\] once daily \[QD\]) or crizotinib (250 mg BID) orally, respectively.
Epistemonikos ID: 2f3e449813f5b17776d45a2b50094f7428a2bcbc
First added on: May 10, 2024